Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The Company’s lead program is a drug that addresses the core disease processes of pulmonary arterial hypertension (PAH).